Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer

BACKGROUND: The survival benefits and adverse effects of pembrolizumab 2 mg/kg intravenously (IV) every 3 weeks (Q3W) in advanced non-small lung cancer (NSCLC) are well documented in the literature. Based on pharmacokinetic models, a pembrolizumab 4 mg/kg IV every 6 weeks (Q6W) dosing regimen is als...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubé-Pelletier, Maude, Labbé, Catherine, Côté, Jimmy, Pelletier-St-Pierre, Audrey-Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Lung Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628563/
https://www.ncbi.nlm.nih.gov/pubmed/37364568
http://dx.doi.org/10.1093/oncolo/oyad182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628563/
https://www.ncbi.nlm.nih.gov/pubmed/37364568
http://dx.doi.org/10.1093/oncolo/oyad182

Ejemplares similares